A61K 9/5073
Having two or more different coatings optionally including drug-containing subcoatings
Official title: {having two or more different coatings optionally including drug-containing subcoatings}
A61K9/5073 (Having two or more different coatings optionally including drug-containing subcoatings) appears on 1,927 US grants and 2,773 published applications in this corpus.
Search patents in A61K- Granted patents
- 1,927
- Published applications
- 2,773
- Assignees
- 1,064
- Inventors
- 4,258
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1976 | 2 | 0 |
| 1977 | 2 | 0 |
| 1978 | 4 | 0 |
| 1979 | 2 | 0 |
| 1980 | 3 | 0 |
| 1981 | 5 | 0 |
| 1982 | 5 | 0 |
| 1983 | 5 | 0 |
| 1984 | 3 | 0 |
| 1985 | 4 | 0 |
| 1986 | 7 | 0 |
| 1987 | 19 | 0 |
| 1988 | 17 | 0 |
| 1989 | 33 | 0 |
| 1990 | 30 | 0 |
| 1991 | 23 | 0 |
| 1992 | 19 | 0 |
| 1993 | 33 | 0 |
| 1994 | 35 | 0 |
| 1995 | 35 | 0 |
| 1996 | 33 | 0 |
| 1997 | 52 | 0 |
| 1998 | 34 | 0 |
| 1999 | 35 | 0 |
| 2000 | 40 | 0 |
| 2001 | 49 | 18 |
| 2002 | 29 | 51 |
| 2003 | 46 | 94 |
| 2004 | 30 | 103 |
| 2005 | 21 | 88 |
| 2006 | 28 | 100 |
| 2007 | 19 | 109 |
| 2008 | 19 | 131 |
| 2009 | 16 | 118 |
| 2010 | 47 | 139 |
| 2011 | 31 | 143 |
| 2012 | 46 | 106 |
| 2013 | 63 | 116 |
| 2014 | 103 | 139 |
| 2015 | 77 | 169 |
| 2016 | 89 | 187 |
| 2017 | 104 | 136 |
| 2018 | 90 | 102 |
| 2019 | 87 | 118 |
| 2020 | 82 | 103 |
| 2021 | 86 | 111 |
| 2022 | 51 | 97 |
| 2023 | 66 | 77 |
| 2024 | 74 | 103 |
| 2025 | 68 | 65 |
| 2026 | 26 | 50 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- Prolonged-release pharmaceutical composition for oral administration of sultiame6 Oct 2026US 12,751,928 B2Advicenne
- Pharmaceutical composition comprising meloxicam22 Sep 2026US 12,740,988 B2Mylan Laboratories Limited
- Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics8 Sep 2026US 12,728,110 B2Flamel Ireland Limited
- Delayed-release formulation of duloxetine1 Sep 2026US 12,721,817 B1Almatica Pharma LLC
- Muco-adhesive, controlled release formulation of levodopa and/or esters of levodopa and uses thereof28 Jul 2026US 12,691,074 B2Impax Laboratories, LLC
- Muco-adhesive, controlled release formulation of levodopa and/or esters of levodopa and uses thereof1 Oct 2026US 2026/0294817 A1Impax Laboratories, LLC
- Compositions and methods of controlling mammalian satiety24 Sep 2026US 2026/0284002 A1VitaKey Inc.
- Sustained adjunct therapy to improve chemotherapy efficacy in glioblastoma in a cerebrovascula tumor-on-a-chip model3 Sep 2026US 2026/0256702 A1Ohio State Innovation Foundation
- Pharmaceutical formulations comprising naltrexone and/or bupropion13 Aug 2026US 2026/0232599 A1Nalpropion Pharmaceuticals LLC
- Pellet of dabigatran etexilate or pharmaceutically acceptable salt thereof6 Aug 2026US 2026/0224545 A1Bostal Drug Delivery Co., Ltd.
Most cited
By later US patents
- Particle immobilized coatings and uses thereof1,386US 8,679,454 B2SurModics, Inc. · 2014
- Controlled release formulations coated with aqueous dispersions of acrylic polymers1,011US 5,639,476 AEuro-Celtique S. A. · 1997
- Solid carriers for improved delivery of active ingredients in pharmaceutical compositions930US 6,248,363 B1Lipocine Inc. · 2001
- Photopolymerizable biodegradable hydrogels as tissue contacting materials and controlled-release carriers896US 5,410,016 ABoard of Regents, The University of Texas System · 1995
- Solid carriers for improved delivery of active ingredients in pharmaceutical compositions684US 6,923,988 B2Lipocine Inc. · 2005